Holen Sie sich die Stockscreener-App
7.57
1.05%
-0.08
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Does Adding Jim Yong Kim to Leadership Shift ImmunityBio’s Global Strategy Narrative (IBRX)? - simplywall.st
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - Bybit
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
ImmunityBio appoints Jim Yong Kim as vice chairman - Investing.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - ImmunityBio
Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next - webull.com
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken In - The National Law Review
Analysts Have Been Trimming Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target After Its Latest Report - 富途牛牛
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - finance.yahoo.com
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value - Sahm
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses - Yahoo Finance
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake - Stock Titan
Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake - Yahoo Finance
HC Wainwright Increases Earnings Estimates for ImmunityBio - MarketBeat
ImmunityBio | 10-Q: Q2 2026 Earnings Report - Moomoo
ImmunityBio Releases Q2 2026 Financial Results - AlphaStreet
ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings - MarketBeat
ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Immunitybio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunitybio Inc earnings missed by $0.14, revenue topped estimates - Investing.com
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M - marketscreener.com
ImmunityBio 2Q 2026: Revenue $51.24M, EPS ($0.22) — 10-Q Summary - TradingView
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
ImmunityBio: Q2 Earnings Snapshot - Barchart.com
ImmunityBio posts Q2 2026 product revenue $50.7M; H1 revenue $94.8M, cash $357.4M - TradingView
ImmunityBio Q2 revenue rises 92% to record $50.7 million - Quiver Quantitative
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings - 24/7 Wall St.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million - Business Wire
ImmunityBio, Inc. (IBRX) Stock Analysis: Assessing a 78% Potential Upside in Cutting-Edge Immunotherapy - DirectorsTalk Interviews
Weekly Recap: U.S. papillary-only label expansion and UAE ANKTIVA approval - TradingView
ImmunityBio, Inc. (IBRX) Options Chain - Yahoo! Finance Canada
Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC - TradingView
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - Benzinga
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - TradingView
UAE Gives ANKTIVA World’s First Approval Across BCG-Unresponsive Bladder Cancer - Stock Titan
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX|Immunitybio Inc|Price:7.000|Chg%:-0.100 - TradingKey
ImmunityBio (IBRX) Projected to Announce Earnings on Tuesday - MarketBeat
PATRICK SOON-SHIONG - Orange County Business Journal
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference - Yahoo Finance
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immunitybio Inc (IBRX) Institutional Confidence - TradingKey
Immunitybio Inc (IBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):